Citius Oncology, Inc. (NASDAQ: CTOR) Stock Competitors & Peer Comparison
See CTOR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CTOR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CTOR | $0.75 | -0.92% | 72.5M | -1.66 | -$0.47 | N/A |
| LLY | $1,185.71 | -0.52% | 1.1T | 37.64 | $31.49 | +0.55% |
| JNJ | $259.24 | +0.88% | 624.7B | 24.16 | $10.73 | +2.04% |
| ABBV | $246.04 | +0.89% | 434.4B | 24.13 | $10.19 | +2.79% |
| MRK | $128.57 | +0.16% | 317.5B | 40.05 | $3.21 | +2.61% |
| NVS | $156.33 | +1.37% | 297.2B | 17.99 | $8.69 | +3.03% |
| AZN | $161.42 | +0.88% | 250.3B | 17.43 | $9.26 | +1.30% |
| AMGN | $410.95 | +1.51% | 221.8B | 18.37 | $22.37 | +2.39% |
| NVO | $47.26 | +2.81% | 209.8B | 11.75 | $4.02 | +3.82% |
| GILD | $133.21 | +1.80% | 165.4B | -341.56 | -$0.39 | +2.42% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
CTOR vs LLY Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while LLY trades at $1,185.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas LLY's P/E ratio is 37.64. In terms of profitability, CTOR's ROE is -0.99%, compared to LLY's ROE of +0.93%. Regarding short-term risk, CTOR is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
CTOR vs JNJ Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, JNJ has a market cap of 624.7B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while JNJ trades at $259.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas JNJ's P/E ratio is 24.16. In terms of profitability, CTOR's ROE is -0.99%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, CTOR is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
CTOR vs ABBV Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, ABBV has a market cap of 434.4B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while ABBV trades at $246.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas ABBV's P/E ratio is 24.13. In terms of profitability, CTOR's ROE is -0.99%, compared to ABBV's ROE of -1.37%. Regarding short-term risk, CTOR is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
CTOR vs MRK Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, MRK has a market cap of 317.5B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while MRK trades at $128.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas MRK's P/E ratio is 40.05. In terms of profitability, CTOR's ROE is -0.99%, compared to MRK's ROE of +0.18%. Regarding short-term risk, CTOR is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check MRK's competition here
Novartis AG (NYSE: NVS)
CTOR vs NVS Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, NVS has a market cap of 297.2B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while NVS trades at $156.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas NVS's P/E ratio is 17.99. In terms of profitability, CTOR's ROE is -0.99%, compared to NVS's ROE of +0.30%. Regarding short-term risk, CTOR is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
CTOR vs AZN Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, AZN has a market cap of 250.3B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while AZN trades at $161.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas AZN's P/E ratio is 17.43. In terms of profitability, CTOR's ROE is -0.99%, compared to AZN's ROE of +0.22%. Regarding short-term risk, CTOR is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
CTOR vs AMGN Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, AMGN has a market cap of 221.8B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while AMGN trades at $410.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas AMGN's P/E ratio is 18.37. In terms of profitability, CTOR's ROE is -0.99%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, CTOR is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
CTOR vs NVO Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, NVO has a market cap of 209.8B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while NVO trades at $47.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas NVO's P/E ratio is 11.75. In terms of profitability, CTOR's ROE is -0.99%, compared to NVO's ROE of +0.59%. Regarding short-term risk, CTOR is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
CTOR vs GILD Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, GILD has a market cap of 165.4B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while GILD trades at $133.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas GILD's P/E ratio is -341.56. In terms of profitability, CTOR's ROE is -0.99%, compared to GILD's ROE of -0.16%. Regarding short-term risk, CTOR is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
CTOR vs PFE Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, PFE has a market cap of 152.4B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while PFE trades at $26.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas PFE's P/E ratio is 8.77. In terms of profitability, CTOR's ROE is -0.99%, compared to PFE's ROE of +0.05%. Regarding short-term risk, CTOR is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
CTOR vs BMY Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, BMY has a market cap of 132.2B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while BMY trades at $64.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas BMY's P/E ratio is 10.91. In terms of profitability, CTOR's ROE is -0.99%, compared to BMY's ROE of +0.47%. Regarding short-term risk, CTOR is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check BMY's competition here
GSK plc (NYSE: GSK)
CTOR vs GSK Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, GSK has a market cap of 106.1B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while GSK trades at $52.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas GSK's P/E ratio is 11.44. In terms of profitability, CTOR's ROE is -0.99%, compared to GSK's ROE of +0.24%. Regarding short-term risk, CTOR is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check GSK's competition here
Sanofi (NASDAQ: SNY)
CTOR vs SNY Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, SNY has a market cap of 104.4B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while SNY trades at $43.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas SNY's P/E ratio is 9.47. In terms of profitability, CTOR's ROE is -0.99%, compared to SNY's ROE of +0.06%. Regarding short-term risk, CTOR is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check SNY's competition here
Biogen Inc. (NASDAQ: BIIB)
CTOR vs BIIB Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, BIIB has a market cap of 30.7B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while BIIB trades at $207.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas BIIB's P/E ratio is 13.13. In terms of profitability, CTOR's ROE is -0.99%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, CTOR is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check BIIB's competition here
Zoetis Inc. (NYSE: ZTS)
CTOR vs ZTS Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, ZTS has a market cap of 30.5B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while ZTS trades at $72.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas ZTS's P/E ratio is 11.04. In terms of profitability, CTOR's ROE is -0.99%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, CTOR is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check ZTS's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
CTOR vs HZNP Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas HZNP's P/E ratio is 61.86. In terms of profitability, CTOR's ROE is -0.99%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, CTOR is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
CTOR vs GRFS Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, GRFS has a market cap of 6.7B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while GRFS trades at $7.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas GRFS's P/E ratio is 9.12. In terms of profitability, CTOR's ROE is -0.99%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, CTOR is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
CTOR vs OGN Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while OGN trades at $13.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas OGN's P/E ratio is 4.06. In terms of profitability, CTOR's ROE is -0.99%, compared to OGN's ROE of +0.23%. Regarding short-term risk, CTOR is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check OGN's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
CTOR vs CELG-RI Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, CELG-RI has a market cap of 224.5M. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while CELG-RI trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -0.99%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, CTOR is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check CELG-RI's competition here
Scilex Holding Company (NASDAQ: SCLX)
CTOR vs SCLX Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, SCLX has a market cap of 59M. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while SCLX trades at $6.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas SCLX's P/E ratio is -0.18. In terms of profitability, CTOR's ROE is -0.99%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, CTOR is more volatile compared to SCLX. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
CTOR vs SCLXW Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, SCLXW has a market cap of 58.9M. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while SCLXW trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas SCLXW's P/E ratio is -0.01. In terms of profitability, CTOR's ROE is -0.99%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, CTOR is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check SCLXW's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
CTOR vs MIRA Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, MIRA has a market cap of 31.1M. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while MIRA trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas MIRA's P/E ratio is -0.51. In terms of profitability, CTOR's ROE is -0.99%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, CTOR is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check MIRA's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
CTOR vs BDSIW Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, CTOR's ROE is -0.99%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, CTOR is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
CTOR vs CRXT Comparison August 2026
Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 72.5M. In comparison, CRXT has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.75 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.66, whereas CRXT's P/E ratio is -0.02. In terms of profitability, CTOR's ROE is -0.99%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, CTOR is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check CRXT's competition here